Cat. No.: HY-19543

Brusatol

(Synonyms: NSC 172924)

45 Cited Publications

Avis client

Based on 45 publication(s) in Google Scholar

Brusatol (NSC 172924) is a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells to Cisplatin and other chemotherapeutic agents. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Brusatol can be developed into an adjuvant chemotherapeutic agent. Brusatol increases cellular apoptosis.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.94%
CAS No.: 14907-98-3
Formule: C₂₆H₃₂O₁₁
Masse moléculaire:520.53

Stockage:

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)

Brusatol Chemical Structure

CAS No.: 14907-98-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (45)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

Nrf2^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	0.067 μM Compound: 9a	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by WST-1 assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by WST-1 assay	[PMID: 33289552]
MCF7	IC₅₀	0.083 μM Compound: 9a	Cytotoxicity against human MCF-7 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MCF-7 cells incubated for 72 hrs by MTT assay	[PMID: 33289552]
MDA-MB-231	IC₅₀	0.081 μM Compound: 9a	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 33289552]
MDA-MB-231	IC₅₀	29.19 nM Compound: Brusatol	Inhibition of NRF2 in human MDA-MB-231 cells harboring ARE-GFP-Luc assessed as reduction in ARE-luciferase activity after 16 hrs by firefly luciferase reporter gene assay Inhibition of NRF2 in human MDA-MB-231 cells harboring ARE-GFP-Luc assessed as reduction in ARE-luciferase activity after 16 hrs by firefly luciferase reporter gene assay	[PMID: 31270017]
PANC-1	IC₅₀	0.36 μM Compound: 9a	Cytotoxicity against human Panc-1 cells incubated for 72 hrs by sulphorhodamine B assay Cytotoxicity against human Panc-1 cells incubated for 72 hrs by sulphorhodamine B assay	[PMID: 33289552]
SW1990	IC₅₀	0.1 μM Compound: 9a	Antiproliferative activity against human SW1990 incubated for 72 hrs by sulphorhodamine B assay Antiproliferative activity against human SW1990 incubated for 72 hrs by sulphorhodamine B assay	[PMID: 33289552]

In Vitro

Brusatol (0.05, 0.15, 0.45, 1.35, 4.05 and 12.15 μg/mL) reduces the viability of CT-26 cells in a dose-dependent manner with IC₅₀ value of 0.27±0.01μg/mL. When Brusatol is combined with Cisplatin (CDDP) at a constant concentration ratio of 1:1, cell growth inhibition is markedly enhanced compared with single-agent treatment; the IC₅₀ value of Brusatol and CDDP cotreatment is 0.19±0.02μg/mL^[2].
Brusatol provokes a rapid and transient depletion of Nrf2 protein, through a posttranscriptional mechanism, in mouse Hepa-1c1c7 hepatoma cells. Brusatol sensitizes mammalian cells to chemical toxicity^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

The murine CT-26 CRC cell line
Concentration:

0.05, 0.15, 0.45, 1.35, 4.05 and 12.15 μg/mL
Incubation Time:

48 hours
Result:

The viability of CT-26 cells was reduced in a dose-dependent manner, with IC₅₀ value of 0.27±0.01 μg/mL.

Western Blot Analysis^[3]

Cell Line:

Mouse Hepa-1c1c7 hepatoma cells
Concentration:

1, 3, 10, 30, 100, 300, and 1000 nM
Incubation Time:

2 hours
Result:

Provoked the depletion of Nrf2, in a concentration-dependent manner within 2 h of exposure to cells.

In Vivo

Brusatol is able to reach the tumor tissue and inhibit the Nrf2 pathway. Nude mice are injected with A549 cells to induce tumor growth, followed by a single i.p. injection of 2 mg/kg Brusatol. Nrf2 protein levels are significantly decreased at 24 h or 48 h postinjection^[1].
Cisplatin (2 mg/kg) or Brusatol (2 mg/kg) alone does not inhibit tumor growth significantly, whereas in the combination group, tumor size is significantly reduced^[1]. "

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Athymic nude mice 4-6 wk old bearing A549 xenografts^[1]
Dosage:

2 mg/kg
Administration:

Treated i.p.; Cisplatin (2 mg/kg), Brusatol (2 mg/kg), or in combination every other day for a total of five times
Result:

Nrf2 protein levels were significantly decreased at 24 h or 48 h postinjection.
Cisplatin or Brusatol alone did not inhibit tumor growth significantly, whereas in the combination group, tumor size was significantly reduced. "

Chemical Information

CAS No. 14907-98-3
Appearance Solid
Masse moléculaire 520.53
Formule C₂₆H₃₂O₁₁
Color White to off-white
SMILES

CC([C@](C[C@@](O1)2[H])3[H])=C(O)C(C[C@]3(C)[C@]4([H])[C@]2(CO[C@@]5([C@@H](O)[C@@H]4O)C(OC)=O)[C@@]5([H])[C@@H](OC(/C=C(C)/C)=O)C1=O)=O
Synonyms

NSC 172924
Structure Classification
- Terpenoids
- Diterpenoids
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)

Publications (45)

All Cell Proliferation/Viability AssayBio/Physico-chemical AssayRT-PCRWB

Sort by:

Journal Impact Factor

Nat Commun

Targeting fatty acid oxidation enhances response to HER2-targeted therapy. [Abstract]

2024 Aug 3;15(1):6587. PMID: 39097623

Brusatol purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 3;15(1):6587. [Abstract]

NIC cells were treated with the Nrf2 inhibitors, Brusatol (100 nM), ML385 (2μM)), or vehicle (DMSO). Proliferation was assessed by Incucyte after 72 h.

Brusatol purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 3;15(1):6587. [Abstract]

Glucose consumption in NIC cells treated with the Nrf2 inhibitors, Brusatol (100 nM), ML385 (2μM)), or vehicle (DMSO) for 72h.

Brusatol purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 3;15(1):6587. [Abstract]

QRT-PCR analysis of Glut1 gene expression in NIC cells treated with the Nrf2 inhibitors, Brusatol (100 nM), ML385 (2μM)), or vehicle (DMSO) for 72h.

Brusatol purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 3;15(1):6587. [Abstract]

Basal, maximal (Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone – FCCP), ATP-synthesis coupled (Oligomycin A), and non-mitochondrial (rotenone/ antimycin A) oxygen consumption rates (OCRs) of NIC cells treated with DMSO or Nrf2 inhibitor Brusatol (100 nM).

Brusatol purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 3;15(1):6587. [Abstract]

Quantification of basal OCR and extracellular acidification rates (ECAR) of NIC cells treated with the Nrf2 inhibitors, Brusatol (100 nM), ML385 (2μM)), or vehicle (DMSO) for 72h.
Adv Sci (Weinh)

ERM Inhibition Confers Ferroptosis Resistance through ROS-Induced NRF2 Signaling. [Abstract]

2026 Mar;13(16):e13310. PMID: 41589654
Adv Sci (Weinh)

Addressing Clinical Limitations of Glutaminase Inhibitors: Novel Strategies for Osimertinib-Resistant Lung Cancer by Exploiting Glutamine Metabolic Dependency. [Abstract]

2024 Dec 16:e2411479. PMID: 39680480
Int J Biol Sci

2026 Apr 23;22(9):4618-4632. PMID: 42157939
Cell Commun Signal

DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway. [Abstract]

2022 Oct 27;20(1):168. PMID: 36303144
Phytomedicine

Brusatol induced ferroptosis in osteosarcoma cells by modulating the Keap1/Nrf2/SLC7A11 signaling pathway. [Abstract]

2025 May 30:144:156912. PMID: 40494017
Phytomedicine

Brusatol inhibits malignant phenotypes and lipid metabolism of osteosarcoma cells by regulating PI3K/AKT and MAPK pathways. [Abstract]

2025 Feb 12:139:156464. PMID: 39970856
Phytomedicine

Proteomic screening identifies brusatol targets TGFβRII to suppresses non-small cell lung cancer metastasis. [Abstract]

2025 Apr:139:156468. PMID: 39978271
Free Radic Biol Med

Therapeutic potential of 2-hexyl-1-decanol in Cutibacterium acnes-induced skin inflammation via modulation of oxidative and inflammatory pathways. [Abstract]

2026 Jun 3:253:596-611. PMID: 42242598
Free Radic Biol Med

BRG1 protects the heart from acute myocardial infarction by reducing oxidative damage through the activation of the NRF2/HO1 signaling pathway. [Abstract]

2020 Nov 20;160:820-836. PMID: 32950688
Neoplasia

ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma. [Abstract]

2021 Dec;23(12):1227-1239. PMID: 34768109
Biomed Pharmacother

Isoliquiritigenin inhibits apoptosis and ameliorates oxidative stress in rheumatoid arthritis chondrocytes through the Nrf2/HO-1-mediated pathway. [Abstract]

2024 Jan:170:116006. PMID: 38091640
Redox Rep

Dexmedetomidine postconditioning attenuates myocardial ischemia/reperfusion injury by activating the Nrf2/Sirt3/SOD2 signaling pathway in the rats. [Abstract]

2023 Dec;28(1):2158526. PMID: 36738240
Antioxidants (Basel)

Astrocytic Nrf2 Mediates the Neuroprotective and Anti-Inflammatory Effects of Nootkatone in an MPTP-Induced Parkinson's Disease Mouse Model. [Abstract]

2023 Nov 13;12(11):1999. PMID: 38001852
J Agric Food Chem

Lycopene Alleviates Chronic Stress-Induced Liver Injury by Inhibiting Oxidative Stress-Mediated Endoplasmic Reticulum Stress Pathway Apoptosis in Rats. [Abstract]

2022 Nov 16;70(45):14414-14426. PMID: 36318656
Ecotoxicol Environ Saf

Exposure to polystyrene nanoplastics induces hepatotoxicity involving NRF2-NLRP3 signaling pathway in mice. [Abstract]

2024 May 9:278:116439. PMID: 38728945
Food Biosci

2024 Oct.
Food Funct

Chlorogenic acid alleviates chronic restraint stress-induced liver injury potentially via Nrf2-mediated inhibition of ferroptosis and mitochondrial apoptosis. [Abstract]

2026 Jan 26;17(2):1061-1073. PMID: 41524429
Chem Biol Interact

Aldo-keto reductase-7A2 protects against atorvastatin-induced hepatotoxicity via Nrf2 activation. [Abstract]

2024 Apr 25:393:110956. PMID: 38484826
Food Funct

Fucoxanthin alleviated myocardial ischemia and reperfusion injury through inhibition of ferroptosis via the NRF2 signaling pathway. [Abstract]

2023 Nov 13;14(22):10052-10068. PMID: 37861458
Inflammopharmacology

A medicine and food homology formula prevents cognitive deficits by inhibiting neuroinflammation and oxidative stress via activating AEA-Trpv1-Nrf2 pathway. [Abstract]

2024 Dec;32(6):3745-3759. PMID: 39305407
Int J Mol Sci

Natural Compounds, Optimal Combination of Brusatol and Polydatin Promote Anti-Tumor Effect in Breast Cancer by Targeting Nrf2 Signaling Pathway. [Abstract]

2023 May 5;24(9):8265. PMID: 37175972
Front Pharmacol

Brusatol Inhibits Proliferation and Invasion of Glioblastoma by Down-Regulating the Expression of ECM1. [Abstract]

2021 Dec 14:12:775680. PMID: 34970146
Int Immunopharmacol

An indoloquinolinone 3a alleviates lipopolysaccharide-induced acute lung injury by modulating the NF-κB and AMPK/Nrf2 signaling pathways. [Abstract]

2026 Apr 1:174:116398. PMID: 41698296
Int Immunopharmacol

Screening of orthopedic medicines identifies raloxifene hydrochloride as a novel ferroptosis inhibitor for spinal cord injury therapy. [Abstract]

2024 Nov 6;143(Pt 3):113542. PMID: 39510030
Int Immunopharmacol

Knockdown of Smox protects the integrity of the blood-brain barrier through antioxidant effect and Nrf2 pathway activation in stroke. [Abstract]

2024 Jan 5:126:111183. PMID: 37984250
Eur J Pharmacol

Artesunate inhibits atherosclerosis by upregulating vascular smooth muscle cells-derived LPL expression via the KLF2/NRF2/TCF7L2 pathway. [Abstract]

2020 Oct 5;884:173408. PMID: 32739175
Invest Ophthalmol Vis Sci

Perillaldehyde Ameliorates Aspergillus fumigatus Keratitis by Activating the Nrf2/HO-1 Signaling Pathway and Inhibiting Dectin-1-Mediated Inflammation. [Abstract]

2020 Jun 3;61(6):51. PMID: 32579678

Brusatol purchased from MedChemExpress. Usage Cited in: Invest Ophthalmol Vis Sci. 2020 Jun 3;61(6):51. [Abstract]

After pretreatment HCECs with 20 nM Brusatol (BT) for 2 hours, add 0.6 mM PAE or DMSO for 4 hours, and then stimulated with A. fumigatus for 8 hours or 24 hours. The Nrf2 and HO-1 expression declined in normal HCECs pretreated with Brusatol (BT). BT partially inhibits PAE-induced Nrf2 and HO-1 expression in infected HCECs.

Brusatol purchased from MedChemExpress. Usage Cited in: Invest Ophthalmol Vis Sci. 2020 Jun 3;61(6):51. [Abstract]

PCR and ELISA results show the mRNA and protein levels of IL-6, IL-8, and TNF-α after blocking Nrf2 activity. Brusatol (BT) pretreatment partially reverses IL-6, TNF-α, and IL-8 expression levels, which are inhibited by PAE in infected HCECs.
RSC Adv

Self-assembled nanoplatform-mediated co-delivery of brusatol to sensitize sorafenib for hepatocellular carcinoma treatment. [Abstract]

2025 Apr 14;15(15):11675-11687. PMID: 40230634
Nanomedicine

Ginger-derived nanovesicles attenuate osteoarthritis progression by inhibiting oxidative stress via the Nrf2 pathway. [Abstract]

2024;19(28):2357-2373. PMID: 39360651
J Inflamm Res

Protective Effects of Dexmedetomidine on Sepsis-Induced Vascular Leakage by Alleviating Ferroptosis via Regulating Metabolic Reprogramming. [Abstract]

2021 Dec 10;14:6765-6782. PMID: 34916824
Sci Rep

2026 Jun 3. PMID: 42236527
Sci Rep

2026 Apr 3;16(1):15961. PMID: 41933050
Sci Rep

UAMC-3203 inhibits ferroptosis and promotes functional recovery in rats with spinal cord injury. [Abstract]

2024 Aug 30;14(1):20180. PMID: 39215144
Cell Signal

DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis. [Abstract]

2023 May:105:110626. PMID: 36758683
J Immunol Res

Protective Effect of Uric Acid on ox-LDL-Induced HUVECs Injury via Keap1-Nrf2-ARE Pathway. [Abstract]

2021 Nov 1;2021:5151168. PMID: 34761008
Mol Med Rep

Atrial natriuretic peptide protects vertebral endplate chondrocytes against H2O2‑induced apoptosis and oxidative stress through activation of the Nrf2/HO‑1 signaling pathway. [Abstract]

2021 Nov;24(5):754. PMID: 34476501
Toxicol Appl Pharmacol

7,8-Dihydroxyflavone attenuates cisplatin-induced cardiomyocyte apoptosis and mitochondrial dysfunction via the p53/Nrf2 pathway. [Abstract]

2025 Sep 22:505:117578. PMID: 40992637
J Pharm Pharmacol

The combination of astragaloside IV and Panax notoginseng saponins attenuates cerebral ischaemia-reperfusion injury in rats through ferroptosis and inflammation inhibition via activating Nrf2. [Abstract]

2023 Apr 17;75(5):666-676. PMID: 36952592
Mol Biol Rep

Hydrogen treatment attenuates ferroptosis and alleviates spinal cord ischemia-reperfusion injury by activating the Nrf2/HO-1 signaling pathway. [Abstract]

2026 Jan 24;53(1):324. PMID: 41579273
Inhal Toxicol

2026 May;38(5):237-251. PMID: 42011764
Braz J Med Biol Res

Naringin regulates mitochondrial dynamics to protect against acetaminophen-induced hepatotoxicity by activating the AMPK/Nrf2 signaling pathway in vitro. [Abstract]

2022 Oct 17;55:e12040. PMID: 36259797
Research Square Preprint

2024 Dec 02.
bioRxiv

Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors. [Abstract]

2024 Jun 28:2024.06.24.600383. PMID: 38979166
Oxid Med Cell Longev

Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas. [Abstract]

2021 Jun 16:2021:6696015. PMID: 34221237

Solvant et solubilité

In Vitro:

DMSO : 25 mg/mL (48.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9211 mL

9.6056 mL

19.2112 mL

5 mM

0.3842 mL

1.9211 mL

3.8422 mL

10 mM

0.1921 mL

0.9606 mL

1.9211 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (283 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Dongmei Ren, et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1433-8. [Content Brief]

[2]. Hai-Ming Chen, et al. Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells. Int J Mol Med. 2018 Mar;41(3):1447-1454. [Content Brief]

[3]. Adedamola Olayanju, et al. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. Free Radic Biol Med. 2015 Jan;78:202-12. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9211 mL	9.6056 mL	19.2112 mL	48.0280 mL
	5 mM	0.3842 mL	1.9211 mL	3.8422 mL	9.6056 mL
	10 mM	0.1921 mL	0.9606 mL	1.9211 mL	4.8028 mL
	15 mM	0.1281 mL	0.6404 mL	1.2807 mL	3.2019 mL
	20 mM	0.0961 mL	0.4803 mL	0.9606 mL	2.4014 mL
	25 mM	0.0768 mL	0.3842 mL	0.7684 mL	1.9211 mL
	30 mM	0.0640 mL	0.3202 mL	0.6404 mL	1.6009 mL
	40 mM	0.0480 mL	0.2401 mL	0.4803 mL	1.2007 mL

Brusatol

45 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Brusatol

Apoptosis Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Chemotherapy Drug Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Heterocyclic Compound Library

Cell Death Library

Immunopotentiator Compound Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Brusatol

Activité biologique

Chemical Information

Publications (45)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Brusatol Related Classifications

HY-19543 Related Classifications